Lorenzo Galluzzi

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Oncolytic peptides (OLPs) constitute an emerging class of immunotherapeutics that combine direct cancer cell lysis with immune activation. Indeed, OLPs induce rapid immunogenic cell death by disrupting intracellular membranes, which culminates with the abundant release of malignant cell contents including immunostimulatory danger-associated molecular patterns. This results in the engagement of innate immune sensors that potently activate dendritic cells, leading to the cross-priming of tumor-specific T lymphocytes that mediate systemic anticancer immunity. Through such a dual mechanism, OLPs can remodel the tumor microenvironment and overcome resistance to therapy as promoted by intratumoral heterogeneity, hence representing optimal combinatorial partners for immune checkpoint inhibitors. Some OLPs have also shown remarkable clinical efficacy. For instance, LTX-315 (studied as VP-315 in basal cell carcinoma (BCC)) has recently been shown to enable complete and durable responses in patients with BCC, and emerging evidence points to a significant activity of LTX-315 in immunologically cold tumors. Here, we summarize recent mechanistic, preclinical, and clinical advances in OLP development, underscoring their potential as a versatile and powerful modality of cancer immunotherapy.

Year:

2026

Different types of regulated cell death, including ferroptosis, necroptosis, and pyroptosis, can elicit an immune response. In this webinar, our speakers will introduce the concept of inflammatory/immunogenic cell death and discuss its implications for cancer immunity and immunotherapy. The presentations will be followed by a panel discussion and Q A session. The webinar will be hosted by Nature Cancer and Nature Communications editors.

Year:

2025

Mitochondrial permeability transition (MPT)-driven necrosis and necroptosis are regulated variants of cell death that can drive inflammation or even promote antigen-specific immune responses. In oncological settings, indolent inflammatory reactions have been consistently associated with accelerated disease progression and resistance to treatment. Conversely, adaptive immune responses specific for tumor-associated antigens are generally restraining tumor development and contribute to treatment sensitivity. Here, we harnessed female C57BL/6J mice lacking key regulators of MPT-driven necrosis and necroptosis to investigate whether whole-body defects in these pathways would influence mammary carcinogenesis as driven by subcutaneous slow-release medroxyprogesterone acetate (MPA, M) pellets plus orally administered 7,12-dimethylbenz[ a ]anthracene (DMBA, D), an in vivo model that recapitulates multiple facets of the biology and immunology of human hormone receptor positive (HR + ) breast cancer. Our data demonstrate that female mice bearing a whole-body, homozygous deletion in peptidylprolyl isomerase F ( Ppif ), which encodes a key regulator of MPT-driven necrosis commonly known as CYPD, but not female mice with systemic defects in necroptosis as imposed by the whole body-deletion homozygous of receptor-interacting serine-threonine kinase 3 ( Ripk3 ) or mixed lineage kinase domain like pseudokinase ( Mlkl ), are more susceptible to M/D-driven carcinogenesis than their wild-type counterparts. These findings point to CYPD as to an oncosuppressive protein that restrains HR + mammary carcinogenesis in mice, at least potentially via MPT-driven necrosis.

Year:

2025

Autophagy is a highly-conserved mechanism that ensures the lysosomal degradation of disposable or potential toxic cytosolic entities in support of cell survival and adaptation to stress. Autophagy is deregulated in various pathological conditions including cardiovascular, neurological, neoplastic-autoimmune and degenerative disorders. However, clinically relevant pharmacological modulators of autophagy remain elusive, calling for the development of novel screening approaches that are amenable to high throughput/content applications. Here, we describe a simple method to detect autophagy in cultured mammalian cells based on the pH-sensitive fluorescent conjugate CalRexin™:pHrodo™ Red and high throughput/content imaging. CalRexin™:pHrodo™ Red is promptly taken up by endosome-amphisome-autolysosome (low pH ∼4.5) pathway, which is connected to canonical autophagy, culminating with a bright red fluorescence. Importantly, this system allows for the discrimination between autophagic responses coupled with the endosome-amphisome-autolysosome pathways and the endosome-lysosome pathway as elicited by receptor-driven endocytosis and phagocytosis. In human cervical carcinoma sHeLa cells, the accumulation of CalRexin™:pHrodo™ Red as elicited by canonical autophagy activators like the mTOR inhibitor rapamycin or serum starvation was suppressed by conventional inhibitors 3-methyladenine or chloroquine. Similarly, RB1CC1-/-(FIP200) as well as ATG5-/- sHeLa cells (which bear genetic defects in two different steps of autophagy) were unable to accumulate CalRexin™:pHrodo™ Red upon exposure to autophagy activators. Thus, CalRexin™:pHrodo™ Red provides a novel approach for imaging autophagy on high throughout/content platforms to screen large libraries for the identification of novel autophagy-targeting agents.

Year:

2025

Mitochondrial permeability transition (MPT)-driven necrosis and necroptosis are regulated variants of cell death that can drive inflammation or even promote antigen-specific immune responses. In oncological settings, indolent inflammatory reactions have been consistently associated with accelerated disease progression and resistance to treatment. Conversely, adaptive immune responses specific for tumor-associated antigens are generally restraining tumor development and contribute to treatment sensitivity. Here, we harnessed female C57BL/6J mice lacking key regulators of MPT-driven necrosis and necroptosis to investigate whether whole-body defects in these pathways would influence mammary carcinogenesis as driven by subcutaneous slow-release medroxyprogesterone acetate (MPA, M) pellets plus orally administered 7,12-dimethylbenz[ a ]anthracene (DMBA, D), an in vivo model that recapitulates multiple facets of the biology and immunology of human hormone receptor positive (HR + ) breast cancer. Our data demonstrate that female mice bearing a whole-body, homozygous deletion in peptidylprolyl isomerase F ( Ppif ), which encodes a key regulator of MPT-driven necrosis commonly known as CYPD, but not female mice with systemic defects in necroptosis as imposed by the whole body-deletion homozygous of receptor-interacting serine-threonine kinase 3 ( Ripk3 ) or mixed lineage kinase domain like pseudokinase ( Mlkl ), are more susceptible to M/D-driven carcinogenesis than their wild-type counterparts. These findings point to CYPD as to an oncosuppressive protein that restrains HR + mammary carcinogenesis in mice, at least potentially via MPT-driven necrosis.

Year:

2025

Figure S1. (a) Effect of dietary iron levels on ovarian cancer progression. Figure S2. Flow cytometry gating strategy for the analysis of peritoneal cells from mice bearing ID8Defb29/Vegfa tumors that were treated with deferiprone as single agent or in combination with cisplatin. Figure S3. (a-f) Wild-type female mice were implanted with ID8-Defb29/Vegfa tumors and treated as described in Fig 2 d. Figure S4. (a) Representative images of NKp46 staining on the entire omentum. Figure S5. (a) MTT assays for ID8-Defb29/Vegfa, PPNM, and MP cells treated with different concentrations of deferiprone for 12, 24, and 48 hours. Figure S6. (a) Human ovarian cancer cell lines were treated with deferiprone for 48 hours and expression of the indicated genes was analyzed by qRT-PCR. Colors indicate fold change (FC) upon deferiprone treatment compared with vehicle control. Figure S7. (a-b) Mitochondrial iron was traced using mito-ferrogreen in iron-overloaded ID8-Defb29/Vegfa cells that were exposed to deferiprone (100 µM) or vehicle control. Figure S8. (a) Schematic representation of treatment regimens under IFNAR1 blockade related to Fig. 6 a-c.

Year:

2025

NACT-mediated adjuvanticity positively impacts clinically relevant TLS maturation in metastatic HGSOC. A, Representative image of immunofluorescence of CD4, CD8, CD20, CD21, CD23, DC-LAMP, and GZMB staining (immunofluorescence panel 1). Scale bars, 10, 100 and 500 µm. B and C, Distribution of early TLS (eTLS; B ) and mature TLS (mTLS; C ) across pTME and mTME HGSOC tumor samples with/without NACT. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. D, Supervised hierarchical clustering of TLS-relevant gene signature ( CCL2 , CCL3 , CCL4 , CCL5 , CCL8 , CCL18 , CCL19 , CCL21 , CXCL9 , CXCL10 , CXCL11 , and CXCL13 ) across pTME and mTME HGSOC tumor samples with/without NACT. E and F, Overall survival (OS) of 60 ( E ) and 40 chemo-naïve and treated patients with mHGSOC ( F ), respectively (study cohort 1 and 2) based on median stratification of total mTLS. Survival curves were estimated by the Kaplan–Meier method, and differences between groups were evaluated using log-rank test. Number of patients at risk and P values are reported. G, Number of mTLS across patients with CALR Lo and CALR Hi mHGSOC with/without NACT as determined by median stratification. Mean and SEM are shown. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. H and I, OS of 60 and 40 patients with chemo-naïve and treated mHGSOC (study cohorts 1 and 2), upon stratification based on median frequency of mTLS and expression of CALR. Survival curves were estimated by the Kaplan–Meier method, and differences between groups were evaluated using the log-rank test.

Year:

2025

The clinical relevance of combined chemotherapy and immunotherapy in mouse models of TMB Lo and TMB Hi ovarian cancer. A and B, Bar plots showing single-nucleotide variants positions (SNVs) ( A ) and the somatic mutations prevalence (mutations per megabase) ( B ) in ID8 ( n = 3) and Brca1 −/− Trp53 −/− / Myc / Hras SO1 ( n = 3) C57BL/6 syngeneic mouse ovarian cancer cell lines. Mean and SEM are shown. Statistical significance was calculated by multiple t test. P values are indicated. C, Experimental design for the analysis of TLS aggregates development and efficacy of combined chemotherapy and aPD1 and/or aTIM-3 therapy in TMB Lo ID8 and TMB Hi SO1 experimental syngeneic mouse models. D and E, Representative immunostaining for CD4, CD8, CD20, and CD21 ( D ) and a box plot showing density of TLS aggregates within chemo-naïve ( n = 5) and treated TMB Hi SO1 ( n = 9) ovarian tumors ( E ). Scale bars, 100 µm and 2.5 mm. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. F–H, Representative dot plot ( F ) and flow cytometry analyses for percentages of CD62L + CD44 + central memory (CM) and CD62L − CD44 − terminally differentiated CD8 + T cells (TEMRA) ( G ) and TCF1 + PD1 + CD8 + and TIM-3 + PD1 + CD8 + T cells ( H ) in tumor samples of the TMB Hi SO1 experimental model in the presence or absence of carboplatin and taxane chemotherapy (NACT). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. I and J, Overall survival (OS) of TMB Hi SO1 experimental model ( I ) and flow cytometry analyses for percentage of TCF1 + PD1 + CD8 + T cells after NACT, aPD1, aTIM-3 and combined therapy ( J ). Survival curves were estimated by the Kaplan–Meier method, and differences between groups were evaluated using log-rank test. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. K and L, Representative immunostaining for CD4, CD8, CD20, and CD21 ( K ) and a box plot showing density of TLS aggregates within chemo-naïve ( n = 8) and treated TMB Lo ID8 ( n = 8) ( L ) ovarian tumors. Scale bars, 100 µm and 2.5 mm. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. M, Flow cytometry analyses for TCF1 + PD1 + CD8 + and TIM-3 + PD1 + CD8 + T cells in tumor samples of the TMB Lo ID8 experimental model in the presence or absence of carboplatin and taxane chemotherapy (NACT). Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. N, Overall survival (OS) of TMB Lo ID8 experimental model after NACT, anti-PD1, and combined therapy. Survival curves were estimated by the Kaplan–Meier method, and differences between groups were evaluated using log-rank test. P values are indicated. (Panel C created with BioRender.com .)

Year:

2025

NACT-mediated progenitor TCF1 + PD1 + CD8 + T-cell phenotype associates with effector cytotoxic functions within metastatic HGSOC. A–C, Representative dot plot ( A ) and box plot ( B ) showing percentage of TIM-3 + PD1 + CD8 + T cells and GZMB + CD8 + T cells within native pTME and mTME of chemo-naïve and treated HGSOC as determined by flow cytometry. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by the Mann–Whitney test. P values are indicated. C, Marker heatmap dot plots obtained after t-SNE and showing the relative expression of the indicated marker in the different phenotypic clusters within mTME of chemo-naïve and treated HGSOS as determined by flow cytometry. D, Design of experimental and sequencing workflow in 11 patients with HGSOC before and after NACT. scRNAseq was performed on dissociated solid tumor specimens using 10× Genomics Chromium platform. E and F, Uniform manifold approximation and projection (UMAP) plot of all cells ( n = 51,476) passing the quality control, colored by type of therapy ( E ) and cell type ( F ). G and H, TILs projections ( G ) and predicted subtype frequencies ( H ) in biopsies from patients with chemo-naïve and treated HGSOC. CM, central memory; EM, effector memory; MAIT, mucosal-associated invariant T cells; PTEX, progenitor exhausted T cells; TEMRA, terminally exhausted T cells; TEX, exhausted T cells. I and J, Radar plot showing percentage of CD8 + T cells expressing respective T-cell marker ( KLRB1 , TCF7 , CCR7 , IL7R , LMNA , FGFBP2 , XCL1 , CD200 , CRTAM , TOX , PDCD1 , HAVCR2 , and GNLY ; I ) and UMAP showing expression of PDCD1 , HAVCR2 and TCF7 in CD4 + and CD8 + T-cell clusters in chemo-naïve and treated HGSOC samples (study cohort 5; J ), as determined by scRNA-seq. (Panel D created with BioRender.com .)

Year:

2025

Immunomodulation by NACT in metastatic HGSOC. A, Representative images of CALR immunostaining in CALR Lo and CALR Hi patients. Scale bars, 10 and 100 µm. B, CALR expression levels determined by immunostaining and ( C ) ER stress signature level [expression level of DNA damage inducible transcript 3 (DDIT3, best known as CHOP), heat shock protein family A (Hsp70) member 5 (HSPA5, best known as BIP), and heat shock protein 90 beta family member 1 (HSP90B1)] as determined by RNA-seq in pTME and mTME HGSOC with/without NACT. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. D, Supervised hierarchical clustering of gene signatures related to immune populations (orange), immune functions (blue) and immune phenotype (purple) as determined by RNA-seq data from pTME and mTME HGSOC tumor samples with/without NACT. IS, immunosuppression; mDCs, myeloid dendritic cells; NK cells, natural killer cells; TLS, tertiary lymphoid structures. E, Gene expression signature associated with CD8 + T cells, B cells, cytotoxicity, mDCs, TLS, and immunosuppression as determined on RNA-seq data from pTME and mTME HGSOC with/without NACT. Box plots: lower quartile, median, upper quartile; whiskers, minimum, maximum. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. F, Representative image of CD20/DC-LAMP double immunostaining. Scale bars, 500 and 100 µm. G, Density of CD8 + T cells, CD20 + B cells, and DC-LAMP + cells as determined by immunostaining in pTME and mTME HGSOC samples with/without NACT. Mean and SEM are shown. Statistical significance was calculated by two-sided Mann–Whitney test. P values are indicated. ns, not significant.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (34)

Josef Pasulka

Czech Academy of Sciences, Institute of Molecular Genetics

CZECH REPUBLIC
View details

Guido Kroemer

-

FRANCE
View details

Pascal Meier

Principle Investigator

Institute of Cancer Research

UNITED KINGDOM
View details

Hisashi Tanaka

Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Dmitriy Zamarin

Professor and Section Head, Gynecologic Medical Oncology

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Dmitri V. Krysko

Ghent University

BELGIUM
View details

Iain McNeish

Imperial College London

UNITED KINGDOM
View details

David Linley Hare

University of Melbourne

AUSTRALIA
View details

Minkyung Song

Assistant Professor

Sungkyunkwan University

SOUTH KOREA
View details

Michael Lazarou

MONASH UNIVERSITY

AUSTRALIA
View details

Suzanne Cloonan

Associate Professor in Respiratory Biochemistry

Weill Cornell Medicine

UNITED STATES
View details

Sebastian Furness

Future Fellow / Senior Research Fellow

MONASH UNIVERSITY

AUSTRALIA
View details

An Coosemans

Katholieke Universiteit Leuven

BELGIUM
View details

Peter Wookey

Founder/Director/Chief Scientific Officer

Apop Biosciences Pty Ltd

AUSTRALIA
View details

Juan Cubillos-Ruiz

Professor of Microbiology and Immunology

Weill Cornell Medicine

UNITED STATES
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Tomáš Brtnický

Charles University

CZECH REPUBLIC
View details

Francis Jacob

Co-Group leader Ovarian Cancer Research

University Hospital Basel

SWITZERLAND
View details

Diana K. Morales

Associate Professor of Microbiology

Weill Cornell Medical College

UNITED STATES
View details

Deepika Awasthi

Weill Cornell Medicine

UNITED STATES
View details

Oliver Kepp

DR2

INSERM

FRANCE
View details

Monisankar Ghosh

Research Assistant Professor

Stony Brook University

UNITED STATES
View details

Melissa Frey

Associate Professor

Weill Cornell Medicine

UNITED STATES
View details

Giuseppe Ciccotosto

Senior Research Fellow

University of Melbourne

AUSTRALIA
View details

Anna Vähärautio

University of Helsinki

FINLAND
View details

Matias Marin Falco

University of Helsinki

FINLAND
View details

David C. Montrose

Stony Brook University

UNITED STATES
View details

Evelyn Cantillo

Weill Cornell Medicine

UNITED STATES
View details

Asher Wen

Stony Brook University

UNITED STATES
View details

Jan Prochazka

Deputy director, Head of Phenotyping Module

Institute of Molecular Genetics

CZECH REPUBLIC
View details

Pavel Dundr

Charles University

CZECH REPUBLIC
View details

David Cibula

Professor M.D

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC
View details

Hui-Hsuan Kuo

Northwestern University

UNITED STATES
View details

Christopher Mason

Professor

Weill Cornell Medical College

UNITED STATES
View details